Feeding China’s Growing Appetite for Human Albumin
To appreciate how the “Chinese economic miracle” has helped improve access in particular to advanced medical care, one need look no further than its utilization of a single product that is widely used in hospitals to treat severely ill intensive care unit and other patients. That product, now China’s highest dollar-value prescribed therapeutic, is human albumin.
Human Albumin as Drug Therapy for Decompensated Cirrhosis: A New Lifesaving Role for an Old Player?
A growing body of evidence suggests known pharmacologic properties of human albumin may contribute to reducing the risk of a range of cirrhosis complications, including bacterial sepsis, irreversible renal injury and death.
Grifols’ AMBAR Study Findings: Albumin Plasma Exchange May Reduce Progression of Moderate Alzheimer’s Disease
Findings from Grifols’ Phase IIb Alzheimer Management by Albumin Replacement (AMBAR) clinical trial found long-term plasmapheresis with albumin replacement reduced disease progression in a prespecified subset of patients with AD of moderate severity.
The Future of Cord Blood
Once thought to be a useless byproduct, umbilical cord blood now treats more than 80 diseases, and it may soon be used to treat more.
Subcutaneous Immune Globulin Maintenance Therapy for CIDP: An Idea Whose Time Has Come
A potential solution for CIDP patients with these IVIG-related issues is self-administered subcutaneous immune globulin.
Chronic Human Albumin Therapy Prolongs Survival in Patients with Decompensated Cirrhosis
Results from a clinical trial have led investigators to conclude adding longterm administration of human albumin to conventional treatment inpatients with decompensated cirrhosis appears to prolong survival.
Plasma Fractionation: The Challenge of Keeping Pace with Global IG Demand
The success of IG manufacturing assures that today and in the future, patients in need have access to this unique therapeutic.
CSL Behring Will Discontinue Carimune NF in Third Quarter 2018
Discontinuation of the product is due to the preference among healthcare professionals and patients for newer, more advanced immune globulin options.
Plasma Exchange with 5% Albumin Associated with Marked Stabilization of Brain Perfusion in Alzheimer’s
Plasma exchange with 5% albumin replacement was associated with marked stabilization of brain perfusion in patients with mild to moderate Alzheimer’s disease during a 21-week treatment period and reduced perfusion loss compared to control subjects at six-month follow up, according to findings from a sham-controlled Phase II clinical trial.
Expanding Uses of IVIG
Researchers are taking a closer look at intravenous immune globulin for its potential to stop the progression of multiple complex conditions from lupus to multiple sclerosis.
